SSA
ALLO icon

Schonfeld Strategic Advisors’s Allogene Therapeutics ALLO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
+53,079
New +$117K ﹤0.01% 2294
2024
Q3 		– Sell
-17,192
Closed -$40.1K – 2010
2024
Q2 		$40.1K Buy
+17,192
New +$50.7K ﹤0.01% 1955
2024
Q1 		– Sell
-35,300
Closed -$113K – 2036
2023
Q4 		$113K Buy
+35,300
New +$100K ﹤0.01% 1607
2023
Q3 		– Sell
-102,285
Closed -$508K – 1741
2023
Q2 		$508K Buy
+102,285
New +$553K ﹤0.01% 1219
2023
Q1 		– Sell
-124,500
Closed -$783K – 2064
2022
Q4 		$783K Sell
124,500
-139,391
-53% -$1.29M 0.01% 1278
2022
Q3 		$2.85M Buy
263,891
+145,491
+123% +$1.98M 0.02% 730
2022
Q2 		$1.35M Buy
118,400
+38,000
+47% +$337K 0.01% 881
2022
Q1 		$732K Buy
+80,400
New +$837K 0.01% 1148
2021
Q4 		– Sell
-40,500
Closed -$1.04M – 2107
2021
Q3 		$1.04M Sell
40,500
-63,779
-61% -$1.51M 0.01% 935
2021
Q2 		$2.72M Buy
+104,279
New +$2.97M 0.03% 623
2019
Q1 		– Sell
-10,000
Closed -$269K – 1035
2018
Q4 		$269K Buy
+10,000
New +$266K 0.01% 857

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Schonfeld Strategic Advisors's ALLO Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 53,079 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2294 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ALLO as recently as Q2 2024.

Schonfeld Strategic Advisors first reported a position in ALLO in Q4 2018 and has held it in 11 quarters since. The position peaked at $2.85M in Q3 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Schonfeld Strategic Advisors held 53,079 shares of Allogene Therapeutics worth $110K as of Q2 2026.
  • Allogene Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2294 holding.
  • Schonfeld Strategic Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 11 quarters since.
  • Schonfeld Strategic Advisors's Allogene Therapeutics position peaked at $2.85M in Q3 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.